M
Michel Bouvier
Researcher at Université de Montréal
Publications - 412
Citations - 33931
Michel Bouvier is an academic researcher from Université de Montréal. The author has contributed to research in topics: Receptor & G protein-coupled receptor. The author has an hindex of 97, co-authored 396 publications receiving 31267 citations. Previous affiliations of Michel Bouvier include École Polytechnique de Montréal & University of Catania.
Papers
More filters
Journal ArticleDOI
Size-Reduced Macrocyclic Analogues of [Pyr1]-apelin-13 Showing Negative Gα12 Bias Still Produce Prolonged Cardiac Effects.
Kien My Tran,Xavier Sainsily,Jérôme Côté,David Coquerel,Pierre Couvineau,Sabrina Saibi,Lounès Haroune,Élie Besserer-Offroy,Joël Flynn-Robitaille,Martin Resua Rojas,Alexandre Murza,Jean-Michel Longpré,Mannix Auger-Messier,Olivier Lesur,Michel Bouvier,Eric Marsault,Pierre-Luc T. Boudreault,Philippe Sarret +17 more
TL;DR: The synthesized and then evaluated novel macrocyclic compounds of Ape13 to identify agonists with specific pharmacological profiles, leading to the development of analogues 39 and 40, which possess reduced molecular weight and produce a sustained cardiac response up to 6 h after a single subcutaneous bolus injection.
Journal ArticleDOI
Signal Transduction Profiling of Angiotensin II Type 1 Receptor With Mutations Associated to Atrial Fibrillation in Humans
Sarah C. Simões,André L. Balico-Silva,Lucas T. Parreiras-e-Silva,André L B Bitencourt,Michel Bouvier,Claudio M. Costa-Neto +5 more
TL;DR: In this paper, the authors investigated the effect of mutations in the AT1 receptor (AT1R) signal transduction profile, including I103T-A244S, on β-arrestin 2 recruitment and showed that the same mutation led to downstream modulation of kinase pathways.
Journal ArticleDOI
Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity
TL;DR: In this article, pharmacological chaperones (PCs) that restore folding and plasma membrane trafficking by stabilizing near native protein conformation may represent valid therapeutic avenues for the treatment of melanocortin type 4 receptor-linked (MC4R-linked) obesity.
Journal ArticleDOI
Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
E. Scott Priestley,Jacques Banville,Daniel H. Deon,Laurence Dubrez,Marc Gagnon,Julia Guy,Philippe Lapointe,Jean-François Lavallée,Alain Martel,Serge Plamondon,Roger Remillard,Edward H. Ruediger,François Tremblay,Shana L. Posy,Victor R. Guarino,Jeremy M. Richter,Jian-Qiao Li,Anuradha Gupta,Muthalagu Vetrichelvan,T.J. Balapragalathan,Arvind Mathur,Ji Hua,Mario Callejo,Jocelyne Guay,Chi Shing Sum,Mary Ellen Cvijic,Carol A. Watson,Pancras C. Wong,Jing Yang,Michel Bouvier,David Gordon,Ruth R. Wexler,Anne Marinier +32 more
TL;DR: Both compounds demonstrated excellent antithrombotic efficacy and minimal bleeding time prolongation in monkey models relative to the clinically important antiplatelet agent clopidogrel and provide a potential opportunity to improve the standard of care in the treatment of arterial thrombosis.
Journal Article
Non-cholinergic neural excitation of the human rectum induced by acetorphan, an inhibitor of enkephalinase.
TL;DR: Investigation of the effects of acetorphan on the electrical activity of human rectum shows that the rectum is supplied by a rich enkephalinergic innervation, and suggests that the neurotransmitter responsible for this effect is continuously released by the nervous structures implicated in the control of rectal motility.